TTM
-198.7%
YoY change
+144.11pp
Trough year (2020)
-657.6%
Peak year (2019)
-58.9%
Latest annual
-159.2%
EBITDA Margin history chart for Tango Therapeutics (TNGX) from 2019 to 2025
Latest: -159.2%
EBITDA Margin change chart for Tango Therapeutics (TNGX) from 2019 to 2025
Latest: +144.11pp
EBITDA Margin history table for Tango Therapeutics (TNGX) from 2019 to 2025
| 2025 | -159.2% | +144.11pp | ||
| 2024 | -303.3% | -31.73pp | ||
| 2023 | -271.6% | +156.89pp | ||
| 2022 | -428.5% | -274.45pp | ||
| 2021 | -154.0% | +503.61pp | ||
| 2020 | -657.6% | -598.71pp | ||
| 2019 | -58.9% | — |
- 2025-159.2%+144.11pp
- 2024-303.3%-31.73pp
- 2023-271.6%+156.89pp
- 2022-428.5%-274.45pp
- 2021-154.0%+503.61pp
- 2020-657.6%-598.71pp
- 2019-58.9%—
EBITDA Margin values are taken from Tango Therapeutics's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA Margin at Tango Therapeutics (TNGX)
According to Tango Therapeutics's latest reported financial statements, the company's latest reported EBITDA margin is -198.7%. EBITDA margin is EBITDA divided by revenue — earnings before interest, taxes, depreciation, and amortization as a percentage of sales. By stripping out non-cash charges and capital-structure effects, it approximates operating cash profitability and is widely used to compare companies with different asset bases and leverage.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of Tango Therapeutics (TNGX) EBITDA margin is -159.19% – expanded 144.1 percentage points year-over-year.
The highest annual EBITDA margin of -58.90% was reported in 2019. The lowest in the available history was -657.61% in 2020.
Tango Therapeutics EBITDA Margin by Year
Tango Therapeutics EBITDA Margin 2025: -159.2%
2025's EBITDA margin for Tango Therapeutics came in at -159.19%, expanded 144.1 percentage points from 2024.
Tango Therapeutics EBITDA Margin 2024: -303.3%
Tango Therapeutics posted EBITDA margin of -303.30% in 2024, contracted 31.7 percentage points from 2023.
Tango Therapeutics EBITDA Margin 2023: -271.6%
In 2023, Tango Therapeutics reported EBITDA margin of -271.57%, expanded 156.9 percentage points from 2022.
Tango Therapeutics EBITDA Margin 2022: -428.5%
Tango Therapeutics EBITDA margin in 2022 was -428.46%, contracted 274.5 percentage points from 2021.
Tango Therapeutics EBITDA Margin 2021: -154.0%
Tango Therapeutics EBITDA margin in 2021 was -154.00%.
See more financial history for Tango Therapeutics (TNGX).
Sector peers by EBITDA Margin
Healthcare peers of Tango Therapeutics (TNGX), ranked by their latest EBITDA margin
| 55.4% | |
| 46.6% | |
| 45.9% | |
| 34.6% | |
| 33.9% | |
| 30.3% | |
| 26.9% | |
| 5.1% |
- 55.4%
- 46.6%
- 45.9%
- 34.6%
- 33.9%
- 26.9%
Frequently asked questions
Tango Therapeutics (TNGX) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation